Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study
This study evaluated the effects of aclidinium bromide 400 μg and glycopyrronium bromide 50 μg on these parameters. Patients with stable severe/very severe COPD were randomized in this double-blind, double-dummy, crossover, Phase IV study. Patients received single doses of each drug on separate days. Primary endpoints were changes in residual volume (RV) and intra-thoracic gas volume (ITGV), assessed by full-body plethysmography. Other endpoints included changes variations in lung ventilation inhomogeneity (Phase III slope of single-breath nitrogen washout test, SBN2), dyspnoea visual analogue scale, and pulmonary speci...
Source: Pulmonary Pharmacology and Therapeutics - January 12, 2016 Category: Respiratory Medicine Source Type: research
Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP
This study assessed the effect of aclidinium bromide combined with formoterol on COPD lung (n=20) and non-COPD lung (n=10) derived epithelial cells stimulated with TGF-β1 + carbachol on: (i) the generation of mesenchymal cells in relation to epithelial cells, (II) extracellular matrix (ECM) deposition, and (iii) the interaction of ECM on the generation of epithelial and mesenchymal cells. TGF-β1 + carbachol enhanced the generation of mesenchymal cells, which was significantly reduced by aclidinium bromide or formoterol. The effect of combined drugs was additive. Inhibition of p38 MAP kinase and Smad by specific inhibitor...
Source: Pharmacological Research - November 5, 2015 Category: Drugs & Pharmacology Source Type: research
Comparison between anticholinergic and beta-2 agonist treatments by using pletismography and impulse oscillometry
COPD (chronic obstructive pulmonary disease) treatment includes both anticholinergic and beta-2 agonist inhaled bronchodilators which can relieve symptoms and reduce exacerbations. To evaluate the effect of bronchodilator drugs, FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) are routinely measured, even if they don't often fully identify important mechanical modifications of the lung, e.g. hyperinflation. Body plethysmography and impulse oscillometry (IOS) can better evaluate lung function. We recruited 32 patients: 16 with COPD, 10 with ACOS (asthma COPD overlap syndrome) and 6 with bronchial ...
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Bini, F., De Bernardi, G., Grassi, N., Vaghi, A. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Conclusion: Superiority in peak FEV1 and non-inferiority in TDI were demonstrated for aclidinium/formoterol FDC vs SAL/FLU in pts with stable COPD. Improvements in quality of life and exacerbations were similar in both groups. More pts preferred Genuair to Accuhaler. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Vogelmeier, C., Paggiaro, P. L., Dorca, J., Sliwinski, P., Mallet, M., Kirsten, A.-M., Seoane, B., Segarra, R. M., Leselbaum, A., Gil, E. G. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD
Conclusion: Both doses of aclidinium/formoterol FDC demonstrated rapid, sustained improvements in lung function over 24 weeks versus placebo and the monotherapies in patients with COPD. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Singh, D., D'Urzo, A. D., Donohue, J. F., Chuecos, F., Leselbaum, A., Gil, E. G. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Conclusions: Aclidinium/formoterol and salmeterol/fluticasone FDCs were well tolerated in patients with COPD. Incidence of CV AEs was low. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Beier, J., Vogelmeier, C., Mroz, R., Pascual, S., Segarra, R. M., Lei, A., De Miquel, G. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Assessing the Cost-Effectiveness of using Aclidinium Bromide 400 µG /Formoterol Fumarate Dihydrate 12 µG Compared to Aclidinium Bromide 400 µG in the Management of Moderate to Severe Chronic Obstructive Pulmonary Disease
This study aimed to assess the cost-effectiveness of FDC 400/12 µg against the LAMA, aclidinium bromide 400 µg (AB 400 µg). (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Ramos, J Haughney, N Henry, L Lindner, M Lamotte Source Type: research
Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population
ConclusionsInhaled aclidinium (400 μg) was shown to be safe and efficacious in Korean patients with moderate‐to‐severe COPD.Clinical trial registration: NCT01636401 at Clinicaltrials.gov (Source: Respirology)
Source: Respirology - September 15, 2015 Category: Respiratory Medicine Authors: Sang Haak Lee, Jongmin Lee, Kwang Ha Yoo, Soo‐Taek Uh, Myung Jae Park, Sang Yeub Lee, Jae Yeol Kim, Deog Kyeom Kim, Seung Joon Kim, Kwan Ho Lee, Chul‐Gyu Yoo Tags: Original Article Source Type: research
Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease
Expert Review of Respiratory Medicine, Ahead of Print. (Source: Expert Review of Respiratory Medicine)
Source: Expert Review of Respiratory Medicine - August 24, 2015 Category: Respiratory Medicine Tags: article Source Type: research
Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT).
Methods:
Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV
1
]/forced vital capacity (Source: BioMed Central)
Source: BioMed Central - August 1, 2015 Category: Journals (General) Authors: Eric BatemanKenneth ChapmanDave SinghAnthony D’UrzoEduard MolinsAnne LeselbaumEsther Gil Source Type: research
Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed‐dose combination compared with individual components: A phase I, open‐label, single‐dose study
This article is protected by copyright. All rights reserved (Source: Clinical Pharmacology in Drug Development)
Source: Clinical Pharmacology in Drug Development - June 19, 2015 Category: Drugs & Pharmacology Authors: Rainard Fuhr, Anne Leselbaum, Jordi Aubets Tags: Original Article Source Type: research
Aclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary disease.
Authors: Cazzola M, Calzetta L, Matera MG
Abstract
This review will be focused on the development of aclidinium bromide/formoterol fumarate (ACLI/FORM) fixed-dose combinations (FDC) that have been granted marketing authorization by the European Commission to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). ACLI/FORM FDC has been studied in 2 pivotal trials involving over 3,400 patients with COPD, in which it was compared with ACLI alone, FORM alone and placebo. The addition of FORM to ACLI resulted in greater bronchod...
Source: Drugs of Today - June 4, 2015 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease
Exacerbations of chronic obstructive pulmonary disease (COPD) have important consequences for lung function, health status and mortality. Furthermore, they are associated with high economic costs, predominantly related to hospitalization. They are managed acutely with short-acting bronchodilators, systemic corticosteroids or antibiotics; however, a large proportion of COPD exacerbations are unreported and therefore untreated or self-managed. There is evidence to suggest that these unreported exacerbations also have important consequences for health status; therefore, reducing exacerbation risk is an important goal in the m...
Source: Therapeutic Advances in Respiratory Disease - May 19, 2015 Category: Respiratory Medicine Authors: Jones, P. W. Tags: Reviews Source Type: research
Aclidinium bromide/formoterol fumarate dry-powder inhaler: a guide to its use in chronic obstructive pulmonary disease in the EU
Abstract
The use of a dry-powder inhaler containing both aclidinium bromide (a long-acting antimuscarinic agent) and formoterol fumarate (a long-acting β2-selective adrenoreceptor agonist) [Duaklir® Genuair®] is an effective, convenient and well-tolerated option for the maintenance treatment of adults with chronic obstructive pulmonary disease (COPD). Aclidinium/formoterol 340/12 µg twice daily provided rapid and durable improvements in lung function, as well as improvements in COPD control, symptoms and health status outcomes, in clinical trials in patients with stable moderate to severe COPD. (Sour...
Source: Drugs and Therapy Perspectives - March 30, 2015 Category: Drugs & Pharmacology Source Type: research
Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease
The recent Global Initiative for Chronic Obstructive Lung Disease (GOLD) chronic obstructive pulmonary disease (COPD) guidelines consider symptoms and exacerbation history in addition to the degree of airflow obstruction for classifying patients. The improvement of symptoms is principally provided by bronchodilators, using β2 agonists and antimuscarinic agents. Aclidinium bromide is a novel long-acting antimuscarinic agent licensed for use in patients with COPD. Novel fixed-dose combinations that are either licensed or in their late phase of development include vilanterol/umeclidinium, indacaterol/glycopyrronium, olod...
Source: Therapeutic Advances in Respiratory Disease - March 27, 2015 Category: Respiratory Medicine Authors: Babu, K. S., Morjaria, J. B. Tags: Reviews Source Type: research
